Stockholm, Sweden, June 27, 2007 The Swedish pharmaceutical company Moberg Derma AB today announced that it has received approval from the Swedish Medical Products Agency (MPA) to initiate a clinical multi-centre phase III trial for its novel nail fungus project K101. The trial will include up to 470 patients in Swedenand in at least one more country. Patient enrolment is planned to startin September 2007, and full data is expected by the end of 2008.
